Comparison · NCT00736099-5948d87d
Old Lina vs New Lina: Number of Patients With Abnormalities in Vital Signs
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Old Lina vs New Lina: Number of Patients With Abnormalities in Vital Signs. Trial comparisons, record NCT00736099-5948d87d. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00736099-5948d87d
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0 | 0.0025 | wilson | |
| Risk in group 2 | 0 | 0.000000000000000000434 | 0.00648 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.00648 | 0.0025 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Old Lina | Patients pre-treated with linagliptin | 0 | 1,532 | OG000 |
| Group 2 | New Lina | Patients pre-treated with placebo | 0 | 589 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Patients With Abnormalities in Vital Signs
- Description
- Vital sign abnormalities (any abnormalities found during PE or ECG are reported with adverse events)
- Time frame
- 78 weeks
- Population
- Treated Set: all screened patients who were documented to have taken at lease 1 dose of study drug.
Source ClinicalTrials.gov
Trial
- Title
- Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM
- NCT number
- NCT00736099
- Phases
- PHASE3
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- linagliptine 5 mg, linagliptine 5 mg and pioglitazone 30 mg
- Lead sponsor
- Boehringer Ingelheim
- Results first posted
- 2012-03-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00736099?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00736099-5948d87d